A Randomized, Observer-blinded, Parallel-group, Active-control, Phase I/II Trial Of The Safety, Immunogenicity, And Tolerability Of 20 µg, 60 µg, And 200 µg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years

A Randomized, Observer-blinded, Parallel-group, Active-control, Phase I/II Trial Of The Safety, Immunogenicity, And Tolerability Of 20 µg, 60 µg, And 200 µg Of Meningococcal Group B Rlp2086 Vaccine In Healthy Children And Adolescents Aged 8 To 14 Years